{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:17:54Z","timestamp":1791152274274,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T00:00:00Z","timestamp":1361145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Complete eradication of hepatitis <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) is rarely achieved. Treatment options include currently available nucleos(t)ide analogues and pegylated interferon. The aim of our exploratory study was to assess the effectiveness of sequential therapy for chronic hepatitis <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content>) <jats:italic>vs<\/jats:italic> the current standard of care. We evaluated an association with entecavir and pegylated interferon alfa\u20102a (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) in 20 patients with hepatitis <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>, high <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> viremia and genotypes <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> B<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> C<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>. Patients received entecavir alone for 12\u00a0weeks, then entecavir and <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> for 12\u00a0weeks, lastly <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> alone for 36\u00a0weeks. The results were compared with 20 patients (control group) treated in the past with 48\u00a0weeks of <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> monotherapy. Our results show that complete sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) and partial <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> were, respectively, 60% and 80% in the study group and 10% and 30% in the control group; anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>e seroconversion rate were 76.9% <jats:italic>vs<\/jats:italic> 15%, and anti\u2010<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s seroconversion were 20% <jats:italic>vs<\/jats:italic> 0%, respectively. We found a correlation among different genotypes and virological and serological outcomes \u2013 genotype <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> has a better virological response, while genotype <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content> had a better serological response, and <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content> genotype had a poor response. These results show that a sequential approach is a promising strategy of treatment in patients with <jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content> and high viremia in comparison with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> monotherapy. The <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content> genotype seems to have the worse rate of response and requires other treatment strategies.<\/jats:p>","DOI":"10.1111\/jvh.12018","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T03:42:17Z","timestamp":1361245337000},"source":"Crossref","is-referenced-by-count":35,"title":["Sequential therapy with entecavir and <scp>PEG\u2010INF<\/scp> in patients affected by chronic hepatitis <scp>B<\/scp> and high levels of <scp>HBV\u2010DNA<\/scp> with non\u2010<scp>D<\/scp> genotypes"],"prefix":"10.1111","volume":"20","author":[{"given":"L.","family":"Boglione","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cariti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Milia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Simiele","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Nicol\u00f2","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ghisetti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Perri","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Amedeo di Savoia Hospital University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60207-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-828672"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22977"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00011"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1635109100"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-010-0041-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01006.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.1112"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840400407"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.4.562"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04555.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00997.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00247.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26819"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00639.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01332.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06541.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100502"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02390.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22760"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22744"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23722"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22853"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01326.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965350801300217","article-title":"Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence","volume":"13","author":"Wiegand J","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.618"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12018","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T01:27:52Z","timestamp":1698629272000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/jvh.12018"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12018","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,18]]}}}